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ABSTRACT
Because medication adherence is critical to improving the virologic and immunologic response
to therapy and reducing the risk of drug resistance, it is important that we understand the
predictors of nonadherence. The goal of the current study is to examine demographic, health
behavior and psychosocial correlates (e.g., stressful life events, depressive symptoms) of non-
adherence among a sample of HIV infected men and women from one south Florida metro-
politan area. We collected questionnaire data from on 105 HIV infected men and women who
were taking antiretroviral medication during the years 2004 to 2007. In this sample, 44.8% had
missed a medication dose in the past 2 weeks, and 22.1% had missed their medication dur-
ing the previous weekend. Those with three or more stressful life events in the previous 6
months were 2.5 to more than 3 times as likely to be nonadherent (in the past 2 weeks and
previous weekend, respectively) compared to those without such events. Fully 86.7% of those
with six or more stresses were nonadherent during the prior 2 weeks compared to 22.2% of
those with no stressors. Although alcohol consumption, drug use, and symptoms of depres-
sion were related to nonadherence in the bivariate analyses, the effects of these predictors
were reduced to nonsignificance by the stressful event measure. These findings underscore




ALTHOUGH HIGHLY ACTIVE ANTIRETROVIRALTHERAPY (HAART) has reduced morbidity
and mortality in HIV infection,1 adherence to
medication regimens is critical to improving
the virologic and immunologic response to
therapy.2,3 Medication nonadherence increases
the risk of developing multiple drug resistant
strains of HIV, faster disease progression, and
worse survival.2,4 Despite the importance of
adherence to drug regimens, studies consis-
tently show poor adherence among HIV in-
fected persons.5,6
Because medication adherence is critical in the
treatment of HIV, there is a growing body of re-
search examining predictors of adherence, such
as, socioeconomic status,7–9 health behaviors 
(alcohol and drug use),5,8–13 and psychosocial 
factors (stress, depression).2,5,6,8,9,14–19 Although
there is extensive research on the association of
depression with nonadherence, only three stud-
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ies have examined the role of recent stressful life
events.18–20 All showed that stressful events were
associated with nonadherence. Two studies18,19
measured adherence using short (and perhaps
less valid21) time frames (2–4 days); one study
examined the number of reasons for missing
medication doses.20 Furthermore, stressful
events and lifetime trauma have been shown in
some studies to be stronger correlates of nonad-
herence compared to depression.8,18 The associ-
ation of stressful events with nonadherence may
imply a different treatment strategy (e.g., stress
management) than the association of depression
with nonadherence. Clearly, we need more stud-
ies examining the relative importance of stress-
ful events and depression on nonadherence over
longer and varying recall time frames.
The goal of the current study is to examine
demographic, health behavior and psychoso-
cial correlates of nonadherence, using several
recall time frames, among a sample of HIV in-
fected men and women. We hypothesized that
nonadherence would be related to more alco-
hol and illicit drug use, more depressive symp-
toms, and more stressful life events.
METHODS
Sample and procedure
We collected data from February 2004 to Feb-
ruary 2007 on 158 HIV-infected men and
women at study entry before starting a ran-
domized stress or trauma treatment interven-
tion. Of the 158 participants, 105 were taking
antiretroviral medications and thus comprise
the sample for the current paper. Almost all of
those on antiretroviral medications (96%) were
on HAART.
All subjects were recruited from South
Florida (Miami-Dade and Broward Counties)
using newspaper and newsletter advertise-
ments, and by making contact with community
organizations, doctor’s offices, sexually trans-
mitted disease clinics, and word of mouth. Al-
though subjects were part of a stress and/or
trauma treatment study (writing about stress/
trauma), we assumed the stress of HIV was suf-
ficient to enter the study and did not require
the presence of additional trauma. The treat-
ment study did require excluding those: less
than 18 and greater than 68 years of age, who
were illiterate or could not speak, read and
write in English, with active systemic diseases
or disorders that would interfere with partici-
pation or confound prediction of disease pro-
gression (e.g., heart, lung, kidney, liver, cancer,
stroke), with current alcohol or substance de-
pendence, planning to change HIV medication
in the next 6 months or recently changed HIV
medications in the past three months, and ini-
tiating use of antidepressant medication dur-
ing the 1 month before the study. The Institu-
tional Review Board at the University of Miami
approved the study, and all patients signed an
informed consent.
Information from participants was obtained
from questionnaires completed in a private
room and taking approximately 45 minutes to
complete. We also performed a blood draw to
assay baseline CD4 T lymphocyte number and
HIV RNA viral load.
Measures
To measure nonadherence to antiretroviral
medication, we administered the questionnaire
developed by the Patient Care Committee and
the Adherence Working Group of the Out-
comes Committee of the Adult AIDS Clinical
Trial Group.22 The following question in refer-
ence to their HIV treatment was asked, “When
was the last time you missed any of your med-
ications?” We defined nonadherence in several
ways; first it was defined as missing medica-
tions in the past 2 weeks (0  none missing, 1 
nonadherent). We used this recall time frame
because a recent meta analysis of adherence in-
terventions showed that longer recall periods
(2 weeks and 1 month) may be more sensitive,23
particularly as medication regimens have sim-
plified. As in other studies,24 there was a trend
for this 2-week recall time point to be associ-
ated with undetectable HIV RNA viral load 
( 400 copies per milliliter) (e.g., 74% of the ad-
herent had undetectable viral load compared
to 58.7% of the nonadherent (2  2.53, p 
0.11, n  96). To ensure that the longer recall
time period did not make a difference in the re-
sults, we also examined whether subjects
missed any of their HIV medications in the pre-
vious weekend (Saturday or Sunday), because
adherence tends to be more problematic on
weekends. Furthermore, to establish consis-
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tency in the findings regardless of recall time
frame, we also report nonadherence (missing
any medication) during the past week, past
month, and past 3 months.
Recent stressful life events were measured
using a modified version of the Life Events Sur-
vey (LES)25,26 that assessed the presence of
stressful events during the 6 months before the
baseline assessment. This measure was shown
to correlate with poor health related function-
ing in a large sample of HIV infected persons
in the rural southeast.27 The list of events was
modified from the LES to include only those
events that were considered moderate to se-
verely stressful based on our previous studies
with interviewer based objectively rated
stresses.28–30 This objective rating was shown
to be consistently related to immune decline
and HIV disease progression.28–30 For the cur-
rent analysis, we examined number of stresses
out of 43 including: change in relationships
(e.g., marriage, divorce, estrangement from
family), death or serious illness of family mem-
bers or close friends, work/financial problems
(e.g., unemployment, worked long hours, large
drop in income), illness (non-HIV), accidents or
safety issues (e.g., physical or sexual assault),
crime or legal problems (e.g., subject or close
relative arrested, burglarized), other life
changes (e.g., you or partner became pregnant,
moved residence more than once). To avoid
outliers, we truncated the number of stresses at
10; all but two subjects had 10 or fewer stresses.
To avoid confounding patient’s mood with rat-
ings of adherence, we count the number of
events, ignoring patient ratings of distress.
The Beck Depression Inventory (BDI) is a 21-
item instrument that assesses cognitive, affec-
tive, and somatic symptoms of depression.31
The BDI has acceptable Cronbach   0.81 for
nonpsychiatric subjects, and is highly corre-
lated with other depression measures.
We examined several health behaviors, in-
cluding smoking, drinking alcohol, and drug
use. Cigarette smoking was coded as 0  no,
1  yes. We computed the number of alcoholic
drinks (glass of wine, can of beer, shot of liquor)
per month by multiplying the number of days
drinking by usual number of drinks consumed.
We truncated 8 responses at 25, due to outliers.
Illicit drug use (0  no, 1  yes) included us-
ing any of the following substances in the past
month: cocaine, heroin, other injecting drugs
(e.g., ketamine), opiates, amphetamines, hallu-
cinogens, and sedatives/tranquilizers.
The questionnaire also included demo-
graphic and background data on age, gender,
education (coded 1 [less than eighth grade] to
6 [graduate school]), household income (coded
1 [$5000 or less] to 9 [over $70,000]), race/eth-
nicity (coded as two dummy variables, African
American and Hispanic, with Caucasian as the
comparison), and gay or bisexual orientation.
Statistical analyses
Descriptive data were run on all variables in-
cluding means, standard deviations, and me-
dians on continuous variables, and percentages
on all categorical variables. We ran separate bi-
variate logistic regression models with each de-
mographic, background, health behavior, and
psychosocial variable predicting nonadher-
ence. African American and Hispanic dummy
variables were entered into models together
(with Caucasian as the comparison group) to
test the effect of race/ethnicity. To test the pri-
mary hypotheses of this study, we used logis-
tic regression with nonadherence measures as
our outcomes. We used a stepwise analysis
strategy, entering variables into equations in
the following steps: (1) demographic and back-
ground variables including age, education,
household income, gender, gay and race/eth-
nicity (two dummy variables, African Ameri-
can and Hispanic) and (2) number of total re-
cent stresses in the previous 6 months,
depression symptoms, and health behaviors
(smoking, alcohol consumption, drug use). We
allowed variables to stay in the models if p 
0.10 at the step it went in. We show the results
of these stepwise logistic regression analyses as
well as all variables in the model that had a sig-
nificant bivariate relationship with each non-
adherence measure.
RESULTS
Description of the sample
Descriptive information about the sample is
shown in Table 1. The sample of 105 HIV-in-
fected persons had an average age of 44, 61.0%
were male, approximately half had a high
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school degree or less, and most had household
incomes at or below $20,000 per year (74.0%).
Most were minorities (81.9%) including African
Americans (56.2%) and Hispanics (25.7%);
47.1% were gay or bisexual.
In terms of health habits, approximately half
(51.0%) smoked cigarettes, approximately a
third (34.3%) used illicit drugs (e.g., cocaine,
opiates, amphetamines) in the past month, but
only 37.6% drank alcoholic beverages in the
past month. The median number of stressful
events in the past 6 months was 3. The most
common stressors included: worsening finan-
cial status or chronic financial stress (41.4%),
serious arguments or separation from partner
(23.8%), estrangement from family (23.8%), ma-
jor illness or injury (not HIV related; 19.1%), se-
rious illness or injury of close family member(s)
(18.1%), trouble finding employment (17.3%),
death of close friend (16.4%), death of close
family member(s) (15.2%), and marriage or en-
gagement (15.2%). Average depressive symp-
toms was 11.2, with 21.0 % meeting criteria for
depression using a cutoff of 19 for moderate
depression.31 In all, 44.8% had missed a med-
ication dose in the past 2 weeks, and 22.1%
missed at least one dose during the previous
weekend.
Bivariate relationship of nonadherence to
demographic, behavior, and psychosocial variables
Table 2 shows bivariate logistic regression
odds ratios and confidence intervals (CI) of
each demographic, behavioral, and psycholog-
ical variable with each nonadherence measure.
Regardless of nonadherence definition, drink-
ing more alcohol, more stressful events and
greater depressive symptoms were associated
with nonadherence. Gay men had greater like-
lihood of reporting nonadherence during the
past 2 weeks, and those who smoked cigarettes
or used drugs had greater odds for skipped
medication during the previous weekend. Age,
education, household income, gender, race,
and ethnicity were not significantly related to
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TABLE 1. DESCRIPTIVE INFORMATION ABOUT THE SAMPLEa
Characteristic Mean (SD) %
Age in years (range, 24–68) 43.95  8.99
Education
Less than high school degree 28.6
High school degree 21.9
Some college/trade school 27.6
College graduate or beyond 21.9
Household income












Alcohol (drinks per month) (range, 0–25) 4.64  8.00
Drug use (past month) 34.3
Number of stressful events (range 0–10) 3.15  2.53
Depressive symptoms (0–36) 11.17  9.16
Nonadherence (skipped within past two-weeks) 44.8
Nonadherence (skipped past weekend) 22.1
aContinuous variables are reported as means  standard deviations; categorical variables
are listed as percentages. n  105, except gay sexual orientation, household income and
nonadherence in the past weekend was based on 104, smoking was based on 102, and
drinking was based on 101, due to missing data.
either measure of nonadherence, although
there was a trend for younger persons to miss
their medication during the past weekend (p 
0.054).
Multivariate relationship of nonadherence to
demographic, behavior, and psychosocial variables
Logistic regression analyses in Table 3
shows that having more stressful events in the
previous six months was associated with both
measures of adherence. For each increase in
one stressor, the odds of reporting missed
medication in the past two weeks increased
by 36%. For every 3-point (median) increase
in stressful events, there was a 2.5 times
greater odds of nonadherence in the past 2
weeks. Figure 1 shows this stressful events
and nonadherence relationship graphically;
among those with no or one stressful event,
22.2% were nonadherent compared to 86.7%
of those with six or more stresses. On the
short-term nonadherence measure, persons
with three stressful events had 3.2 times the
likelihood of missing medication during the
past weekend compared with those having no
stressors.
In addition to stressful events, those who
were gay reported about 2.7 times greater odds
of missed medication during the past 2 weeks
compared to heterosexuals, but were not dif-
ferent on nonadherence reported during the
past weekend. There was a nonsignificant
trend for cigarette smoking to be related to non-
adherence during the previous weekend, but
no relationship of smoking to nonadherence
measured for the past 2 weeks. Although in bi-
variate analyses, depressive symptoms and
drinking more alcohol were related to both
measures of adherence, and drug use was re-
lated to missing medication during the previ-
ous weekend, the effects of these variables were
diminished by the inclusion of stressful events
in the equations. Stressful life events was mod-
erately correlated with depressive symptoms
(r  0.31, p  0.001), greater alcohol consump-
tion (r  0.48, p  0.0001), and drug use (r 
0.23, p  0.02).
To ensure that our findings relative to stress-
ful life events were not due to choosing partic-
ular nonadherence recall time periods, we also
tested models using different cutoffs. Using the
same analysis strategy, we found that stressful
events were related to increased odds of non-
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TABLE 2. BIVARIATE LOGISTIC REGRESSION ODDS RATIOS AND CONFIDENCE INTERVALS (CI) OF DEMOGRAPHIC, 
HEALTH BEHAVIORS AND PSYCHOSOCIAL VARIABLES WITH ADHERENCE MEASURESa
Nonadherence
Skipped in past 2 weeks Skipped in past weekend
Predictor variables Odds ratio 95% CI Odds ratio 95% CI
Age 0.97 0.93–1.02 0.94b 0.89–1.00
Education 1.20 0.88–1.65 0.99 0.68–1.44
Household income 1.12 0.93–1.35 1.04 0.84–1.29
Male gender 0.58 0.26–1.29 0.46 0.17–1.30
Race/ethnicity
African American 0.58 0.20–1.63 1.41 0.35–5.64
Hispanic 0.97 0.30–3.14 1.75 0.39–7.91
Gay 2.74c 1.23–6.09 2.10 0.82–5.43
Cigarette smoking 1.01 0.46–2.21 2.90c 1.02–8.25
Alcohol drinks/month 1.08d 1.02–1.15 1.09d 1.03–1.15
Drug use (past month) 1.64 0.73–3.68 2.59c 1.00–6.68
# of stressful events 1.36d 1.13–1.63 1.54d 1.25–1.92
Depressive symptoms 1.05c 1.00–1.09 1.07d 1.02–1.12
aOdds ratios are from separate logistic regression models that each include a single independent variable, except
African-American and Hispanic are in the model together because they are two dummy variables of race/ethnicity;




adherence reported during the past week (odds
ratio  1.42, CI  1.16–1.75, p  0.0009), month
(odds ratio  1.33, CI  1.10–1.61, p  0.003),
and 3 months (odds ratio  1.34, CI  1.08–
1.66, p  0.007). In this sample, nonadherence
was reported by 37.1% during the past week,
48.6% during the past month, and 64.8% dur-
ing the past 3 months.
DISCUSSION
We found high levels of nonadherence (44%)
during the past 2 weeks in this sample of pa-
tients from a large metropolitan city. Our high
levels of nonadherence were similar to other
studies.5,6,18 Stressful life events was consis-
tently associated with missing HIV medication,
regardless of the recall time period used in as-
sessing adherence (from preceding weekend to
three months). For every increase of three
stressful events, the odds of nonadherence
were increased 2.5 to over 3 times, depending
on the recall time period. Stressful life events
have also been linked to faster HIV disease pro-
gression.29,32–34 The current findings showing
that stress is associated with medication non-
adherence may be a possible mediator of this
stress/health relationship.
Although symptoms of depression were re-
lated to nonadherence in the bivariate analysis,
depression decreased to nonsignificance when
the stressful event measure was in the equa-
tion. Other studies have also shown that de-
pression was unrelated to nonadherence when
trauma or life events were considered.8,18
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TABLE 3. NONADHERENCE WITH DEMOGRAPHIC, BACKGROUND, HEALTH BEHAVIORS, AND PSYCHOSOCIAL VARIABLESa
Nonadherence: skipped in past 2 weeks
Model 1 Model 2
Odds ratio 95% CI p value Odds ratio 95% CI p value
Gay 2.55 1.04–6.28 0.041 2.73 1.17–6.39 0.020
Alcohol drinks/month 1.03 0.97–1.10 0.344
# of stressful events 1.26 1.02–1.58 0.037 1.36 1.12–1.64 0.002
Depressive symptoms 1.02 0.97–1.08 0.365
Nonadherence: skipped past weekend
Odds ratio 95% CI p value Odds ratio 95% CI p value
Age 0.99 0.92–1.06 0.737 0.99 0.92–1.06 0.822
Cigarette smoking 3.06 0.89–10.54 0.076 2.98 0.92–9.58 0.068
Alcohol drinks/month 1.04 0.97–1.11 0.290
Drug use (past month) 1.60 0.48–5.37 0.446
# of stressful events 1.33 1.03–1.71 0.030 1.47 1.17–1.86 0.0007
Depressive symptoms 1.04 0.98–1.11 0.171
aTable shows two models. Model 1 shows the logistic regression including all predictor variables that had p  0.10
bivariate relationship with each adherence measure. Model 2 shows the results from multivariable stepwise logistic
regression for each of the adherence measures with predictor variables stepped into the model in two stages: (1) dem-
ographic and background variables (e.g., age, education, racial/ethnic, household income, gender, gay) and (2) psy-
chosocial and health behaviors (e.g., smoking, drug use, alcohol use, number of stresses, depression). Variables with

























Number of Stressful Life Events
FIG. 1. The association of antiretroviral nonadherence
(past 2 weeks) by the number of stressful life events (2 
16.22, p  0.001).
Therefore, having many stressful events may
be a more robust correlate of nonadherence
than depression. Persons who report more
stressful events may have more chaotic lifestyles
that may account for their missed medications.
O’Cleirigh and colleagues20 found that those
with many life events and poor distress toler-
ance endorsed a greater number of reasons for
missing their medication. These findings sug-
gest that while interventions for depression
may be useful, cognitive behavioral interven-
tions that address stress and coping may have
a greater impact on adherence to HIV medica-
tions.23
Gay men had more nonadherence when
measuring missed medication during the pre-
vious 2 weeks, but not when examining the
previous weekend. We could find no other
studies that reported a similar finding and
therefore we need further research to deter-
mine if this is unique to our sample. There was
a nonsignificant trend for smoking cigarettes to
be related to nonadherence during the past
weekend but no relationship with missed med-
ication during the previous 2 weeks. Smoking
has been shown to be positively related to non-
adherence in several studies done in France,35-37
where there has been an emphasis on smoking
cessation in HIV.38 These differences on ad-
herence measures may reflect measurement er-
ror when using varying length recall periods,23
lending support for the multiple measures ap-
proach used here.
Many studies have shown that drinking al-
cohol and drug use are related to nonadher-
ence.5,8–13,35 The current study showed that
these health behaviors were related to nonad-
herence in the bivariate analyses, but that life
stress reduced the effects of these variables to
nonsignificance. Because our sample omitted
those with substance dependence, the relation-
ship of these health behaviors with adherence
is likely to be reduced. However, it is also likely
that persons with many life stressors tend to
use more drugs and alcohol and that those who
use more drugs and alcohol tend to engage in
behaviors that lead to more life stress (e.g., con-
flicts with families, financial and employment
problems). While life stress may be a more po-
tent correlate of nonadherence than poor health
behaviors, effective adherence treatment must
still address issues of substance abuse and de-
pendence.
Interpretation of our study findings must be
balanced against a number of limitations in the
current study design. First, our sample was
drawn from persons volunteering for a psy-
chological treatment study in one south Florida
metropolitan area and may not be representa-
tive of HIV infected persons. Comparing our
sample on stress and trauma to a large popu-
lation based clinic study in the rural southeast33
showed similar levels of recent stress with
somewhat more trauma (e.g., sexual and phys-
ical abuse) in the current urban sample. It is
certainly possible that more trauma history
might affect subject’s ability to manage current
life stress and thus affect the generalizability of
this study.
Second, without longitudinal data it is diffi-
cult to determine the causal nature of the rela-
tionships, although it does seem unlikely that
poor adherence could lead to having more
stressful events. Using discrete events rather
than patient’s ratings of their stress, and mea-
suring stress during the 6 months before base-
line, also helps to establish the causal direction
of this relationship. However, it is always pos-
sible that some third variable might account for
the relationship between stressful events and
nonadherence, despite controlling for many de-
mographic and background characteristics. Fi-
nally, our study is limited by the use of self-re-
port measures of adherence that may not
accurately reflect actual practice. The consis-
tency of the stress findings, regardless of mea-
surement time frame, lends support to the va-
lidity of our results.
This is among the few studies that have ex-
amined the role of stressful life events on med-
ication adherence. Previous studies of stressful
events18,19 have focused on short recall time
frames of adherence. By showing that more
stressful life events correlates with nonadher-
ence using multiple recall time frames (from
short to long), our study demonstrates the ro-
bust nature of these findings. The role of stress-
ful events in medication nonadherence lends
credence to considering cognitive behavioral
interventions that address issues of stress, cop-
ing and chaotic lifestyles for treating inconsis-
tent conformance with medication guidelines.
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These findings underscore the importance of
addressing stressful events within the medical
setting, and providing referrals to psycholo-
gists, social workers or case managers for pa-
tients having many such stressors.
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